You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Clinical Vector for TCR Immunotherapy Targeted to Melanoma

    SBC: LENTIGEN CORPORATION            Topic: NCI

    DESCRIPTION (provided by applicant): This Phase II proposal is a continuation of our Phase I award, Lentiviral Vectors for TCR Immunotherapy Targeted to Melanoma. We have successfully achieved the milestones laid out in our initial application. We generated a lentiviral gene vector capable of expressing a T cell receptor (TCR) specific for the tyrosinase:368-376 epitope, and demonstrated the act ...

    SBIR Phase II 2010 Department of Health and Human Services
  2. A Low Cost Integrated Method for Isolation of M. Tuberculosis DNA from Raw Sputum

    SBC: AKONNI BIOSYSTEMS INC.            Topic: NIAID

    Nucleic acid testing offers the potential to improve tuberculosis diagnosis world wideHigh purity DNA is essential to the success of virtually any downstream nucleic acid detection methodWe propose to develop a sample preparation system to extract and purify Mycobacterium tuberculosis DNA from raw sputumThe project goalas described in the solicitationPHSTopicis to develop an inexpensive and easy t ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Genetically Attenuated Malaria Attenuated Whole Parasite Sporozoite Vaccine

    SBC: SANARIA INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Malaria is responsible for hundreds of millions of cases and a million deaths annually. An ideal tool for eliminating Plasmodium falciparum (Pf), the causative agent of 99% of all malaria deaths, would be a highly effective vaccine that prevents blood stage infection and thereby prevents all disease and transmission. When radiation attenuated Pf sporozoites (Pf ...

    SBIR Phase II 2010 Department of Health and Human Services
  4. Plasmodium vivax recombinant CS protein vaccine for malaria

    SBC: PROTEIN POTENTIAL LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): Plasmodium vivax recombinant CS protein vaccine Plasmodium vivax (Pv) is responsible for hundreds of millions of malaria cases annually, as many cases of malaria in travelers as P. falciparum (Pf), and a substantial economic burden. Severe malaria with mortality due to Pv has recently been reported from Oceania, south Asia, and South America. During the last de ...

    SBIR Phase II 2010 Department of Health and Human Services
  5. Development of Broad Spectrum Host Oriented Therapeutic Antibodies against Influe

    SBC: FUNCTIONAL GENETICS, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Infection with influenza virus causes a highly contagious disease of the respiratory tract. Influenza represents a unique therapeutic challenge due to both seasonal antigen shift and drift. Conventional approaches for therapeutic targeting of influenza pathogens have consistently faced obstacles arising from the development of resistant strains and a lack of br ...

    SBIR Phase II 2010 Department of Health and Human Services
  6. Discovery of Critical Host Genes Enabling Resistance to HIV-1 Infection as Therap

    SBC: FUNCTIONAL GENETICS, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Human Immunodeficiency Virus (HIV-1) is a global threat to public health and poses an unprecedented challenge to drug development. HIV-1 drugs that directly target virus often fail due to rapid emergence of drug resistance. Functional Genetics (FGI) used a proprietary technology, Random Homozygous Gene Perturbation (RHGP) and discovered novel host gene targets ...

    SBIR Phase II 2010 Department of Health and Human Services
  7. PredicTOR: predicting patient response to mTOR pathway inhibitors prior to treatm

    SBC: 20 20 Genesystems Inc            Topic: NCI

    DESCRIPTION (provided by applicant): The promise of personalized medicine relies on the development of diagnostic tests to categorize patients within small cohorts who will benefit from specific treatments. 20/20 GeneSystems, Inc. (20/20) is a small business concern focused on the development of diagnostics for personalized medicine. Towards this end, 20/20 has developed, with the support of the N ...

    SBIR Phase II 2010 Department of Health and Human Services
  8. Lentiviral-MGMT gene transfer into hematopoietic stem cells

    SBC: LENTIGEN CORPORATION            Topic: NCI

    DESCRIPTION (provided by applicant): Therapeutic stem cell gene transfer relies on long-term gene expression achieved by integration of new DNA into the cellular genome. Current clinical trials featuring oncoretroviruses have encountered a number of roadblocks that include low levels of gene transfer, poor expression, and a recognized preferential insertion near promoter regions that increases the ...

    STTR Phase I 2010 Department of Health and Human Services
  9. HUCBC modulation of Alzheimer's-like pathology and behavioral changes

    SBC: SANERON CCEL THERAPEUTICS, INC.            Topic: NIA

    DESCRIPTION (provided by applicant): In the past years, we have shown that human umbilical cord blood cells (HUCBC, U-CORD- CELL ) provide cognitive recovery in animal models of neurodegenerative disease. Infusion of HUCBC resulted in reduced infarct volume as well as in rescue of behavioral benefits in an animal model of stroke. We further showed that HUCBC infusion proved to be beneficial in ani ...

    STTR Phase II 2010 Department of Health and Human Services
  10. DNA repair deficient cells for analysis

    SBC: TREVIGEN, INC.            Topic: NIGMS

    DESCRIPTION (provided by applicant): Successful completion of Phase I led to the development a panel of human cell lines, each deficient in one of the eleven DNA glycosylase enzymes. Depletion of target mRNA was as high as 95%, with corresponding depletion of target protein levels and enzymatic activity. To expand background diversity, the same shRNA lentiviruses were also used to develop parallel ...

    SBIR Phase II 2010 Department of Health and Human Services
US Flag An Official Website of the United States Government